Case 1 was a middle-aged female patient from the EGFR+/METamp- group and a nonsmoker diagnosed with advanced lung adenocarcinoma without brain metastases. She was found to be harboring the EGFR L858R mutation and had de novo MET overexpression (Figure 1a). Baseline measurements in her supraclavicular lymph nodes showed negative MET amplification by FISH. Gefitinib was used as a first-line treatment for 3.8 months, and the best response was partial response (PR).